1 |
CHRM1
| 8件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D00787
D00787
|
Trihexyphenidyl
| 2件: 5 5, 6 |
2 |
CHRM1
| 8件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D08638
D08638
|
Trihexyphenidyl
| 2件: 5 5, 6 |
3 |
CHRM2
| 6件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton | D00787
D00787
|
Trihexyphenidyl
| 2件: 5 5, 6 |
4 |
CHRM2
| 6件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton | D08638
D08638
|
Trihexyphenidyl
| 2件: 5 5, 6 |
5 |
CHRM3
| 11件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D00787
D00787
|
Trihexyphenidyl
| 2件: 5 5, 6 |
6 |
CHRM3
| 11件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D08638
D08638
|
Trihexyphenidyl
| 2件: 5 5, 6 |
7 |
CHRM4
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton | D00787
D00787
|
Trihexyphenidyl
| 2件: 5 5, 6 |
8 |
CHRM4
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton | D08638
D08638
|
Trihexyphenidyl
| 2件: 5 5, 6 |
9 |
CHRM5
| 6件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D00787
D00787
|
Trihexyphenidyl
| 2件: 5 5, 6 |
10 |
CHRM5
| 6件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D08638
D08638
|
Trihexyphenidyl
| 2件: 5 5, 6 |
11 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
12 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
13 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
14 |
ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
15 |
ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
16 |
ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
17 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
18 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
19 |
ADRB3
| 8件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
20 |
DRD1
| 10件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism | D02004
D02004
|
Apomorphine
| 3件: 5 5, 6, 7 |
21 |
DRD1
| 10件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism | D07460
D07460
|
Apomorphine
| 3件: 5 5, 6, 7 |
22 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D02004
D02004
|
Apomorphine
| 3件: 5 5, 6, 7 |
23 |
DRD2
| 8件: Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D07460
D07460
|
Apomorphine
| 3件: 5 5, 6, 7 |
24 |
ABAT
| 7件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism, Propanoate metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse | D00399
D00399
|
Valproic acid
| 17件: 2 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 |
25 |
FDPS
| 4件: Terpenoid backbone biosynthesis Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection | D01968
D01968
|
Zoledronic acid
| 13件: 5 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333 |
26 |
FDPS
| 4件: Terpenoid backbone biosynthesis Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection | D06378
D06378
|
Zoledronic acid
| 13件: 5 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333 |
27 |
FDPS
| 4件: Terpenoid backbone biosynthesis Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection | D06379
D06379
|
Zoledronic acid
| 13件: 5 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333 |
28 |
FDPS
| 4件: Terpenoid backbone biosynthesis Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection | D08689
D08689
|
Zoledronic acid
| 13件: 5 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333 |
29 |
GABRA1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
30 |
GABRA1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
31 |
GABRA2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
32 |
GABRA2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
33 |
GABRA3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
34 |
GABRA3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
35 |
GABRA4
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
36 |
GABRA4
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
37 |
GABRA5
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
38 |
GABRA5
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
39 |
GABRA6
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
40 |
GABRA6
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
41 |
GABRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
42 |
GABRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
43 |
GABRB2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
44 |
GABRB2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
45 |
GABRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
46 |
GABRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
47 |
GABRD
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
48 |
GABRD
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
49 |
GABRE
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
50 |
GABRE
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
51 |
GABRG1
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
52 |
GABRG1
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
53 |
GABRG2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
54 |
GABRG2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
55 |
GABRG3
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
56 |
GABRG3
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
57 |
GABRP
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
58 |
GABRP
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
59 |
GAD1
| 7件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, beta-Alanine metabolism, Taurine and hypotaurine metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse, Type I diabetes mellitus | D00399
D00399
|
Valproic acid
| 17件: 2 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 |
60 |
GAD2
| 7件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, beta-Alanine metabolism, Taurine and hypotaurine metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse, Type I diabetes mellitus | D00399
D00399
|
Valproic acid
| 17件: 2 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 |
61 |
GRIA1
| 14件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
62 |
GRIA2
| 15件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
63 |
GRIA3
| 13件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction, Transcriptional misregulation in cancer | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
64 |
GRIA4
| 10件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
65 |
GRIK1
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
66 |
GRIK2
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
67 |
GRIK3
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
68 |
GRIK4
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
69 |
GRIK5
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
70 |
GRIN1
| 18件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
71 |
GRIN2A
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
72 |
GRIN2B
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
73 |
GRIN2C
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
74 |
GRIN2D
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
75 |
HCRTR1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D10082
D10082
|
Suvorexant
| 3件: 5 5, 6, 13 |
76 |
HCRTR2
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D10082
D10082
|
Suvorexant
| 3件: 5 5, 6, 13 |
77 |
KIT
| 11件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer | D10229
D10229
|
Masitinib
| 6件: 2 2, 5, 6, 13, 46, 96 |
78 |
MAOB
| 14件: Glycine, serine and threonine metabolism Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism | D02562
D02562
|
Rasagiline
| 7件: 2 2, 5, 6, 13, 17, 58, 66 |
79 |
MAOB
| 14件: Glycine, serine and threonine metabolism Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism | D08469
D08469
|
Rasagiline
| 7件: 2 2, 5, 6, 13, 17, 58, 66 |
80 |
MAOB
| 14件: Glycine, serine and threonine metabolism Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism | D10829
D10829
|
Rasagiline
| 7件: 2 2, 5, 6, 13, 17, 58, 66 |
81 |
MAPT
| 4件: MAPK signaling pathway MAPK signaling pathway, Alzheimer disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases | D11210
D11210
|
Flortaucipir
| 3件: 5 5, 7, 127 |
82 |
MAPT
| 4件: MAPK signaling pathway MAPK signaling pathway, Alzheimer disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases | D11293
D11293
|
Gosuranemab
| 1件: 5 5 |
83 |
ACHE
| 2件: Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D00670
D00670
|
Donepezil
| 9件: 5 5, 6, 13, 46, 78, 124, 127, 156, 206 |
84 |
ACHE
| 2件: Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D02558
D02558
|
Rivastigmine
| 3件: 5 5, 6, 13 |
85 |
ACHE
| 2件: Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D03822
D03822
|
Rivastigmine
| 3件: 5 5, 6, 13 |
86 |
ACHE
| 2件: Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D07869
D07869
|
Donepezil
| 9件: 5 5, 6, 13, 46, 78, 124, 127, 156, 206 |
87 |
GABRQ
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00706
D00706
|
Zolpidem
| 3件: 5 5, 6, 46 |
88 |
GABRQ
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D08690
D08690
|
Zolpidem
| 3件: 5 5, 6, 46 |
89 |
PTGS1
| 5件: Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes | D00428
D00428
|
Salsalate
| 1件: 5 5 |
90 |
PTGS1
| 5件: Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes | D01183
D01183
|
Tolfenamic acid
| 1件: 5 5 |
91 |
PTGS2
| 22件: Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer | D00428
D00428
|
Salsalate
| 1件: 5 5 |
92 |
PTGS2
| 22件: Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer | D01183
D01183
|
Tolfenamic acid
| 1件: 5 5 |
93 |
ROCK1
| 20件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Chemokine signaling pathway, Sphingolipid signaling pathway, Vascular smooth muscle contraction, TGF-beta signaling pathway, Axon guidance, Focal adhesion, Tight junction, Platelet activation, Leukocyte transendothelial migration, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Shigellosis, Yersinia infection, Human cytomegalovirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer | D07941
D07941
|
Fasudil
| 4件: 2 2, 5, 7, 51 |
94 |
SNAP25
| 2件: Synaptic vesicle cycle Synaptic vesicle cycle, Insulin secretion | D00783
D00783
|
Botulinum toxin type A
| 13件: 2 2, 5, 6, 7, 13, 15, 17, 36, 51, 70, 113, 149, 226 |
95 |
ALDH5A1
| 3件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Butanoate metabolism, Metabolic pathways | D00399
D00399
|
Valproic acid
| 17件: 2 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 |
96 |
CACNA1I
| 7件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome | D00399
D00399
|
Valproic acid
| 17件: 2 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 |
97 |
CACNA1H
| 7件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome | D00399
D00399
|
Valproic acid
| 17件: 2 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 |
98 |
CACNA1G
| 8件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome | D00399
D00399
|
Valproic acid
| 17件: 2 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 |
99 |
ROCK2
| 21件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Chemokine signaling pathway, Sphingolipid signaling pathway, Vascular smooth muscle contraction, Wnt signaling pathway, Axon guidance, Focal adhesion, Tight junction, Platelet activation, Leukocyte transendothelial migration, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Yersinia infection, Human cytomegalovirus infection, Pathways in cancer, Proteoglycans in cancer, Lipid and atherosclerosis | D07941
D07941
|
Fasudil
| 4件: 2 2, 5, 7, 51 |